T1D Fund Welcomes Anastasia Bukhman to Board to Drive International Type 1 Diabetes Research Collaboration in Boston Massachusetts

The T1D Fund: A Breakthrough T1D Venture, LLC, based in Boston, has strengthened its leadership team with the appointment of philanthropist Anastasia Bukhman to its Board of Directors.

The impact investment fund is dedicated to accelerating innovative therapies aimed at treating, preventing, and ultimately curing type 1 diabetes.

The move comes as the organization deepens its global reach and builds stronger partnerships across the scientific, philanthropic, and investment communities focused on T1D breakthroughs.

Strategic Role as the Fund Expands International Collaboration

In her new position, Bukhman is expected to offer strategic guidance as the T1D Fund broadens its international engagement.

Her appointment is seen as part of a wider effort to connect high-impact philanthropy with cutting-edge medical research and biotech investment.

The fund continues to collaborate closely with major partners, including Breakthrough T1D and the The Leona M. and Harry B. Helmsley Charitable Trust, to support early-stage companies working on disease-modifying treatments.

Philanthropy, Entrepreneurship, and a Growing Research Footprint

Bukhman brings a blend of philanthropic and entrepreneurial experience to the board.

Alongside her husband Igor Bukhman, she co-founded the Bukhman Foundation in 2023, with a mission centered on improving lives through investments in medical science and cultural development.

Beyond philanthropy, she also has business leadership experience as co-founder of the Creative Restaurant Group, adding a commercial and operational perspective to her advisory role.

The Bukhman Foundation has already become a significant contributor to type 1 diabetes research.

Suggested Readings (News continues below)

UK Government Launches £132 Million Funding Scheme to Transform Fisheries and Revive Coastal Communities Across England

ADC US chapter urges INEC and judiciary to resolve political disputes ahead of 2027 elections in Nigeria amid rising leadership confusion and legal tension

UK Ministry of Defence launches powerful NAD Group reform and marks Andy Start retirement milestone across United Kingdom defence system

UK Certification Officer Reviews Union Complaints, Opens New Independence Application and Marks 50 Years of Oversight

Its initiatives include partnerships with Diabetes UK, collaborations with Breakthrough T1D, and the establishment of the Bukhman Centre for Research Excellence in Type 1 Diabetes at the University of Oxford.

In 2025, the foundation also committed $12 million to the T1D Fund to help speed up investment in potential curative therapies.

Leadership Driving the T1D Fund’s Investment Strategy

Launched in 2016, the T1D Fund is led by CEO Elizabeth Mily and operates as a venture-style investment platform focused on advancing breakthrough therapies for type 1 diabetes.

The fund co-invests alongside venture capital firms and biotech companies to support early-stage innovations targeting the underlying causes of the disease.

Its long-term goal is to move beyond treatment and toward transformative, potentially curative solutions.

Impact and Consequences

Bukhman’s appointment is expected to strengthen the fund’s ability to connect global philanthropic capital with high-risk, high-reward biotech innovation.

Her experience and funding network could help accelerate research pipelines and expand the reach of T1D-focused investments into new regions.

The increased collaboration between major charities, research institutions, and private foundations signals a more coordinated global approach to tackling type 1 diabetes.

This could lead to faster clinical development timelines and greater funding stability for early-stage scientific projects.

What’s Next?

With new board leadership in place, the T1D Fund is likely to deepen its partnerships with international research institutions and expand co-investment opportunities in emerging biotech companies.

Attention will also turn to how the fund deploys capital from major contributions like the $12 million commitment from the Bukhman Foundation, particularly in advancing next-generation therapies and potential cure pathways for type 1 diabetes.

Further announcements on new investments and research collaborations are expected as the organization continues to scale its global impact.

Summary

The appointment of Anastasia Bukhman to the T1D Fund Board marks a strategic step in strengthening global collaboration in type 1 diabetes research.

With strong philanthropic backing and established partnerships across leading medical organizations, the fund is positioning itself to accelerate the development of innovative and potentially curative therapies.

Bulleted Takeaways

• The T1D Fund has appointed Anastasia Bukhman to its Board of Directors
• She co-founded the Bukhman Foundation, a major supporter of T1D research
• The foundation has contributed $12M to the T1D Fund in 2025
• Key partnerships include Breakthrough T1D, Diabetes UK, and the University of Oxford
• The T1D Fund focuses on venture-style investments in early-stage cure-oriented therapies
• Leadership is headed by CEO Elizabeth Mily
• The appointment is expected to boost global collaboration and research funding efficiency